A Phase 2, Open-label, Multicenter Study to Explore the Efficacy and Safety of Mongersen (GED-0301) in Subjects With Active Ulcerative Colitis
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 27 Jul 2017
At a glance
- Drugs Mongersen (Primary)
- Indications Ulcerative colitis
- Focus Therapeutic Use
- Sponsors Celgene Corporation
- 27 Jul 2017 According to a celgene corporation media release, data from this trial is expected in second half of 2017.
- 05 May 2017 Planned End Date changed from 1 Dec 2016 to 11 Aug 2017.
- 11 Aug 2016 Status changed from recruiting to active, no longer recruiting.